Jane Street’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$718K Sell
19,500
-4,000
-17% -$108K ﹤0.01% 7236
2026
Q1
$423K Sell
23,500
-37,100
-61% -$744K ﹤0.01% 8440
2025
Q4
$1.42M Sell
60,600
-34,700
-36% -$753K ﹤0.01% 5425
2025
Q3
$1.9M Sell
95,300
-13,400
-12% -$241K ﹤0.01% 5033
2025
Q2
$1.49M Buy
+108,700
New +$1.04M ﹤0.01% 4914
2024
Q3
Sell
-21,400
Closed -$359K 10429
2024
Q2
$359K Buy
+21,400
New +$304K ﹤0.01% 7512
2020
Q4
Sell
-25,000
Closed -$482K 8138
2020
Q3
$482K Hold
25,000
﹤0.01% 5210
2020
Q2
$653K Buy
+25,000
New +$611K ﹤0.01% 4673

Other funds holding URGN

Jane Street's URGN Position: Q2 2026 in Review

Jane Street opened a new position in UroGen Pharma (URGN) in Q2 2026: 9,505 shares worth $350K. The stake represents ﹤0.01% of the portfolio and ranks #8862 among its holdings. This is a return to the name: Jane Street previously reported a position in URGN as recently as Q3 2025.

Jane Street first reported a position in URGN in Q2 2018 and has held it in 17 quarters since. The position peaked at $6.55M in Q3 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Jane Street held 9,505 shares of UroGen Pharma worth $350K as of Q2 2026.
  • UroGen Pharma was a new Jane Street position in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8862 holding.
  • Jane Street first reported a position in UroGen Pharma in Q2 2018 and has held it in 17 quarters since.
  • Jane Street's UroGen Pharma position peaked at $6.55M in Q3 2025.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.